Skip to content

Insulin Degludec/Insulin Aspart

    Brands

    DEA Class; Rx

    Common Brand Names; Ryzodeg

    • Antidiabetics, Insulin Combos

    Insulin degludec: Long-acting basal insulin

    Insulin aspart: Rapid-acting insulin

    Insulin and its analogues lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production; insulin inhibits lipolysis and proteolysis and enhances protein synthesis; targets include skeletal muscle, liver, and adipose tissue

    Indicated to improve glycemic control in adults with diabetes mellitus

    During episodes of hypoglycemia

    Documented hypersensitivity

    Nasopharyngitis (11.1-24.6%)

    Severe hypoglycemia (0.4-13.3%)

    Headache (5.6-9.7%)

    URT infection (5.7-9.1%)

    Influenza (6.9%)

    Peripheral edema (1.8-2.2%)

    Injection site reaction (2%)

    Allergic reaction

    Lipodystrophy

    Localized cutaneous amyloidosis at injection site

    Hypersensitivity

    Hypokalemia

    Do not share, even if the needle is changed; sharing poses a risk for transmission of blood-borne pathogens

    Changes in insulin, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia; these changes should be made cautiously and only under medical supervision, and the frequency of blood glucose monitoring should be increased

    Severe, life-threatening, generalized allergy, including anaphylaxis, can occur

    All insulin products cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia; monitor potassium levels in patients at risk for hypokalemia including patients using potassium-lowering medications or those taking medications sensitive to serum potassium concentrations; treat if indicated

    Thiazolidinediones, which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists can cause dose-related fluid retention, particularly when used in combination with insulin; this may lead to or exacerbate heart failure

    There are no available data in pregnant women to inform a drug-associated risk for major birth defects and miscarriage

    There are no available data in pregnant women to inform a drug-associated risk for major birth defects and miscarriage

    Specific maximum dosage information is not available. Individualize dosage based on careful monitoring of blood glucose and other clinical parameters in all patient populations.

    Insulin degludec/insulin aspart

    prefilled pen

    • insulin degludec 70 units/insulin aspart 30 units per mL (ie, 100 units/mL for combination)